::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

RELATION OF HYPERHOMOCYSTINEMIA IN YOUNG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

AUTHORS:

Dr Zimran Samuel, Dr Rabail Fatima, Dr Yussra Hammad

ABSTRACT:

Aim: The aim of this study is to determine the association of hyperhomocysteinemia with acute myocardial infarction in young patients. Place and Duration: We present an observational study of 12 cases of young patients with documented myocardial infarction at the Cardiology department of Bahawal Victoria Hospital, Bahawalpur for one-year duration from April 2019 to April 2020. Methods: A total of 12 patients were selected for this study. Evidence of myocardial infarction was obtained by ECG, cardiac enzymes, scan or coronary angiography. Common conditions causing hyperhomocysteinemia such as kidney disease, cancer, thyroid disorders, use of antifolate medications were excluded. Hyperhomocysteinemia was classified as moderate (16-30 µmol / l), intermediate (31-100 µmol / l) and severe (> 100 µmol / l). Fasting homocysteine levels were quantified on an Axym Plus System machine (Abbott). Results and Conclusion: Hence hyperhomocystinemia, a thrombotic marker which is being classified as a proximate risk factor, may act synergistically with other classical risk factors to accentuate the risk of CAD in young population. This observation needs further validation with large scale studies to justify for early screening of Homocysteine levels as it is a potentially modifiable risk factor with little economic burden. Key Words: Hyperhomocysteinemia, Myocardial Infarction, atherosclerosis, thrombosis.